Big Pharma (L)Earnings Q2’23 | Gilead, Regeneron, Amgen, Moderna, Bayer, Lilly
Below is round three (and perhaps the final round) of Big Pharma (L)Earnings for this quarter. Given the length of this series, I've included a TLDR section below with my key takes. Enjoy!
TLDR: My Key Takes/Opinions
Gilead
Despite most of the investment community writing off the Immunomedics and Kite acquisitions a couple years after they occurred, both TRODELVY and YESCARTA are looking to be on a great trajectory and still have key inflection points on the horizon to continue growth. Oftentimes it’s hard/unfair to judge the success/failure of a deal until we have a clearer picture of a product's “outs” (in the poker sense).
Regeneron
Dupixent’s development plan is vast and extremely well thought out. If successful, it will provide Regeneron with HUMIRA-like leverage with payers and a sizable moat.
Keep reading with a 7-day free trial
Subscribe to Big Pharma Sharma to keep reading this post and get 7 days of free access to the full post archives.